<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Ther</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Ther</journal-id><journal-title-group><journal-title>Diabetes Therapy</journal-title></journal-title-group><issn pub-type="ppub">1869-6953</issn><issn pub-type="epub">1869-6961</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26620049</article-id><article-id pub-id-type="pmc">4674469</article-id><article-id pub-id-type="publisher-id">147</article-id><article-id pub-id-type="doi">10.1007/s13300-015-0147-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Hirose</surname><given-names>Takahisa</given-names></name><address><email>takahisa.hirose@med.toho-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Suzuki</surname><given-names>Manabu</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Tsumiyama</surname><given-names>Isao</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><aff id="Aff1"><label/>Division of Diabetes, Metabolism and Endocrinology, Department of Medicine, Toho University School of Medicine, Tokyo, Japan </aff><aff id="Aff2"><label/>Development Division, Clinical Development, Cardio-Metabolic Clinical Franchise Department, Novartis Pharma KK, Tokyo, Japan </aff><aff id="Aff3"><label/>Development Division, Clinical Development, Biometrics and Statistical Sciences Department, Novartis Pharma KK, Tokyo, Japan </aff></contrib-group><pub-date pub-type="epub"><day>30</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>30</day><month>11</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>12</month><year>2015</year></pub-date><volume>6</volume><issue>4</issue><fpage>559</fpage><lpage>571</lpage><history><date date-type="received"><day>5</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2015</copyright-statement></permissions><abstract id="Abs1"><sec><title>Introduction</title><p>To assess the efficacy and safety of vildagliptin as add-on therapy in Japanese patients with type 2 diabetes mellitus (T2DM), inadequately controlled on stable long-acting, intermediate-acting, or pre-mixed insulin, with or without concomitant metformin.</p></sec><sec><title>Methods</title><p>In this 12-week placebo-controlled study, patients were randomized to receive either vildagliptin 50&#x000a0;mg twice daily (bid) or placebo treatment in a 1:1 ratio. The primary endpoint was change in glycated hemoglobin A1c (HbA1c) from baseline to 12-week endpoint. Secondary endpoints included proportion of patients achieving pre-defined HbA1c targets of &#x02264;6.5%, &#x0003c;7.0%, and HbA1c &#x0003c;7.0% in patients with baseline HbA1c &#x02264;8.0% and change in fasting plasma glucose (FPG) after 12&#x000a0;weeks of treatment. Regular monitoring was performed to record any treatment-emergent adverse events (AEs) and serious adverse events or hypoglycemic episodes.</p></sec><sec><title>Results</title><p>Of the 156 patients randomized, 96.8% completed the study (vildagliptin, <italic>n</italic>&#x000a0;=&#x000a0;76; placebo, <italic>n</italic>&#x000a0;=&#x000a0;75). Patient demographics and clinical characteristics were comparable between the groups at baseline. Addition of vildagliptin resulted in statistically significant reductions in HbA1c after 12&#x000a0;weeks (&#x02212;1.01&#x000a0;&#x000b1;&#x000a0;0.06%), with a between-treatment difference of &#x02212;0.91&#x000a0;&#x000b1;&#x000a0;0.09% (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). FPG levels reduced from baseline to 12&#x000a0;weeks in the vildagliptin group (&#x02212;1.2&#x000a0;&#x000b1;&#x000a0;0.2&#x000a0;mmol/L), with a between-treatment difference of &#x02212;1.2&#x000a0;&#x000b1;&#x000a0;0.3&#x000a0;mmol/L which was significant (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). The proportion of patients achieving HbA1c targets was higher with vildagliptin treatment for all pre-defined responder rate categories. The overall incidence of AEs was comparable between groups (vildagliptin, 46.2% vs. placebo, 43.6%). The overall incidence of hypoglycemic events was low and all events were self-treatable without using drug therapy. No severe hypoglycemic events were reported.</p></sec><sec><title>Conclusion</title><p>Treatment with vildagliptin 50&#x000a0;mg bid as add-on to insulin with or without metformin resulted in statistically significant reductions in HbA1c in Japanese patients with T2DM. Overall, vildagliptin was well tolerated with a safety profile similar to that of placebo in this patient population.</p><p><bold>ClinicalTrials.gov Identifier</bold>, NCT02002221</p></sec><sec><title>Funding</title><p>Novartis Pharma K.K</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1007/s13300-015-0147-6) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Hypoglycemia</kwd><kwd>Insulin</kwd><kwd>Japanese</kwd><kwd>Type 2 diabetes mellitus</kwd><kwd>Vildagliptin</kwd></kwd-group><funding-group><award-group><funding-source><institution>Novartis Pharma KK</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p>The increasing prevalence of type 2 diabetes mellitus (T2DM) poses a major health crisis globally. According to International Diabetes Federation estimates, 382 million people were affected with T2DM in 2013. This number is projected to increase up to 600 million by 2035, with Asia alone accounting for 60% of this population [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>In Japan, approximately 7 million people aged 20&#x02013;79&#x000a0;years are affected with T2DM and the prevalence is dramatically increasing due to lifestyle changes, genetic predisposition, and the aging population [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Mortality related to diabetes was 44% in patients aged &#x0003c;60&#x000a0;years in Japan, China, and other parts of the Western Pacific region [<xref ref-type="bibr" rid="CR1">1</xref>]. The high prevalence of T2DM is associated with significant economic encumbrance, accounting for up to 6% of the total healthcare budget [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p>Due to the progressive nature of T2DM, treatment intensification with oral antidiabetes drugs (OADs) is often required. However, despite the availability of several OADs and advancements in T2DM management, achieving glycated hemoglobin A1c (HbA1c) goal of &#x0003c;7% is still a challenge in most Asian countries including Japan [<xref ref-type="bibr" rid="CR4">4</xref>]. Impaired insulin secretion and insulin resistance are two major pathophysiological features where insulin secretory response is severely impaired in T2DM patients, especially among Japanese population [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>In Japan, insulin is now being used more frequently, with ~30% of patients receiving either a monotherapy or in combination with other OADs [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Although pre-mixed insulin lowers fasting plasma glucose (FPG) and post-prandial glucose levels to some extent, it eventually fails to demonstrate adequate control over glycemic excursions [<xref ref-type="bibr" rid="CR7">7</xref>]. Fear of increased risk of hypoglycemia and weight gain associated with insulin often results in delay in treatment initiation and intensification [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. In addition, patients undergoing insulin treatment gradually develop a syndrome called Impaired Awareness of Hypoglycemia (IAH), in which the ability to identify the onset of hypoglycemia becomes progressively impaired and thus the complications associated with hypoglycemia increase [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Hence, there is a need for OADs as an add-on to insulin that can improve glycemic control without increasing the risk of hypoglycemia and weight gain. Dipeptidyl peptidase-4 (DPP-4) inhibitors such as vildagliptin are being increasingly used for the treatment of diabetes in Japanese patients [<xref ref-type="bibr" rid="CR12">12</xref>]. Further, concomitant use of insulin and a DPP-4 inhibitor has recently been included in the treatment algorithm [<xref ref-type="bibr" rid="CR6">6</xref>]. The efficacy and tolerability of vildagliptin in combination with insulin, with or without metformin, has been demonstrated in randomized clinical trials in global populations including Asians [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. However, there is still a dearth of data on the efficacy and safety of vildagliptin as an add-on therapy to insulin in Japanese patients with T2DM.</p><p>This 12-week, randomized, placebo-controlled study aimed to assess the efficacy and safety of vildagliptin 50&#x000a0;mg twice daily (bid) add-on therapy in Japanese patients with T2DM, inadequately controlled on insulin, with or without concomitant metformin treatment.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study Design and Patient Population</title><p>This was a 12-week, randomized, double-blind, placebo-controlled study conducted in Japan. Patients were treated with stable once daily (qd) or bid injectable doses (&#x02264;1&#x000a0;unit/kg/day) of long-acting, intermediate-acting, or pre-mixed insulin, with or without metformin, for at least 12&#x000a0;weeks prior to screening. Patient visits were scheduled at week &#x02212;2 (visit 1), week 0, (baseline), and at weeks 4, 8, and 12 (visits 2, 3, and 4, respectively; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Study design. *Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study. <italic>BL</italic>
<sup><italic>&#x020ac;</italic></sup> Baseline, the first day of blinded study medication. **Each patient was instructed to visit the study site within 13&#x000a0;weeks from baseline. <italic>bid</italic> twice daily</p></caption><graphic xlink:href="13300_2015_147_Fig1_HTML" id="MO1"/></fig></p><p>Following a 2-week screening period, men and women, aged between 20 and 75&#x000a0;years, with baseline HbA1c 7&#x02013;10%, body mass index (BMI) 20&#x02013;35&#x000a0;kg/m<sup>2</sup>, fasting C-peptide &#x02265;0.6&#x000a0;ng/mL (&#x02265;0.20&#x000a0;nmol/L), and inadequately controlled on insulin with or without metformin, were randomized. Patients with a history of type 1 diabetes, FPG levels &#x02265;15.0&#x000a0;mmol/L, acute metabolic complications such as ketoacidosis or lactic acidosis, critical liver conditions such as cirrhosis or hepatitis, impaired renal function, congestive heart failure (New York Heart Association Class III or IV), myocardial infarction, stroke or ischemic attacks in past 6&#x000a0;months were excluded from the study. Patients who received rapid- or short-acting insulin except in pre-mixed formulations with either intermediate- or long-acting insulin, or even those on insulin doses taken more frequently than bid, or a total insulin dose exceeding 1&#x000a0;unit/kg/day for the past 12&#x000a0;weeks were also excluded. The dose of insulin was to be maintained within 10% variation from baseline throughout the study unless dose adjustments were required for safety reasons. Patients were stratified based on the use of metformin and type of insulin.</p></sec><sec id="Sec4"><title>Efficacy and Safety Assessments</title><p>The primary endpoint was the change in HbA1c from baseline to 12&#x000a0;weeks. Secondary efficacy endpoints included responder rates based on the proportion of patients achieving the pre-defined glycemic targets of HbA1c &#x02264;6.5%, &#x0003c;7.0%, and HbA1c &#x0003c;7.0% in patients with baseline HbA1c &#x02264;8.0%, HbA1c reduction from baseline to endpoint of &#x02265;1% and &#x02265;0.5%, and change in FPG from baseline to study endpoint. Subgroup analysis based on concomitant use of metformin and insulin types were also performed. Safety assessments included vital signs, body weight, standard hematology, urinalysis and biochemistry test results, as well as recording and regular monitoring of treatment-emergent adverse events (AEs) and serious adverse events (SAEs). Patients were educated on hypoglycemic symptoms in the beginning of the screening period where general reviews on possible triggers and identification of symptoms were shared. At baseline visit, patients were provided with a personal calibrated home glucose monitor and were asked to record the hypoglycemic events in a glycemia study diary. Hypoglycemia was defined as symptoms suggestive of hypoglycemia that was further confirmed by a self-monitored blood glucose measurement of &#x0003c;3.1&#x000a0;mmol/L. The event was considered grade 1 if the patient was able to initiate self-treatment, and grade 2 (severe hypoglycemia) if the patient required assistance of another person or hospitalization. All laboratory assessments were performed at a central facility (LSI Medience Corporation, Tokyo, Japan).</p></sec><sec id="Sec5"><title>Statistical Analysis</title><p>Assuming a withdrawal rate of 5%, a sample size of 152 patients with T2DM treated with insulin were randomized to provide 90% power to detect a clinically significant difference of 0.6% in HbA1c change from baseline between vildagliptin and placebo at a one-sided significance level of 2.5%. nQuery Advisor 7.0 (Statistical Solutions Ltd., Cork, Ireland) was applied for the calculation of sample size based on primary variables of change from baseline in HbA1c at the week-12 endpoint.</p><p>Efficacy analyses were performed on the full analysis set (FAS) population, comprising all randomized patients who received at least one dose of study medication and had one post-randomization efficacy measurement. An analysis of covariance (ANCOVA) model, with treatment, type of insulin (long- or intermediate-acting vs. pre-mixed), and use of metformin as classification variables and baseline HbA1c as a covariate, was used to compare the treatment effect in HbA1c reduction after 12&#x000a0;weeks. Changes in FPG levels from baseline to week 12 were also analyzed using ANCOVA model. The least square mean change and difference from baseline for each treatment group, and the associated one-sided 95% confidence interval (CI) and <italic>p</italic> value for each difference was obtained from the primary analysis model. The percentage of patients who met each of the pre-defined responder criteria was computed and compared using a Chi-Squared test in the FAS. For subgroup analysis, summary of absolute values and changes in HbA1c from baseline to study endpoint were presented on the last observation carried forward-based data for the FAS. Safety analyses were performed on the safety set which included all the patients who received at least one dose of the study drug and were summarized descriptively. All the data analysis for this study was performed using SAS<sup>&#x000ae;</sup> statistical software (version 9.3, SAS Institute Inc., Cary, NC, USA).</p></sec><sec id="Sec6"><title>Ethics and Good Clinical Practice</title><p>The study protocol was reviewed and approved by the Independent Ethics Committee/Institutional Review Board at each participating center. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national), the Declaration of Helsinki of 1964, as revised in 2013 and Good Clinical Practice guidelines. Written informed consent was obtained from all patients prior to inclusion in the study. The study is registered with ClinicalTrials.gov, identifier: NCT02002221.</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Patient Disposition and Baseline Characteristics</title><p>A total of 275 patients were screened based on inclusion/exclusion criteria. Unacceptable laboratory values accounted for 68.9% (<italic>n</italic>&#x000a0;=&#x000a0;119) of screening failures. Out of 156 patients randomized, 96.8% (vildagliptin, <italic>n</italic>&#x000a0;=&#x000a0;76 and placebo, <italic>n</italic>&#x000a0;=&#x000a0;75) completed the study (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The most common reason behind discontinuation was AEs: 2.6% in the vildagliptin and 1.3% in the placebo group. Demographics and baseline characteristics of the patients are presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Both treatment groups were well balanced for baseline characteristics. Men predominated over women (71.2% vs. 28.8%, respectively). The overall mean age&#x000a0;&#x000b1;&#x000a0;SD was 59.3&#x000a0;&#x000b1;&#x000a0;9.3&#x000a0;years, mean BMI was 25.7&#x000a0;&#x000b1;&#x000a0;3.3&#x000a0;kg/m<sup>2</sup>, mean baseline HbA1c was 8.1&#x000a0;&#x000b1;&#x000a0;0.8%, and mean FPG was 8.9&#x000a0;&#x000b1;&#x000a0;2.6&#x000a0;mmol/L. The mean duration of T2DM was ~13&#x000a0;years. More patients were on intermediate-acting insulin (<italic>n</italic>&#x000a0;=&#x000a0;91) compared to pre-mixed insulin (<italic>n</italic>&#x000a0;=&#x000a0;65). The mean daily doses of insulin and metformin were 0.3&#x000a0;&#x000b1;&#x000a0;0.18&#x000a0;unit/kg/day, and 1047.8&#x000a0;mg/day, respectively.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Patient disposition</p></caption><graphic xlink:href="13300_2015_147_Fig2_HTML" id="MO2"/></fig><table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patient demographics and baseline characteristics (randomized set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameters</th><th align="left">Vildagliptin 50&#x000a0;mg bid (<italic>n</italic>&#x000a0;=&#x000a0;78)</th><th align="left">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;78)</th><th align="left">Total (<italic>n</italic>&#x000a0;=&#x000a0;156)</th></tr></thead><tbody><tr><td align="left">Age (years)</td><td align="left">58.5&#x000a0;&#x000b1;&#x000a0;9.6</td><td align="left">60.1&#x000a0;&#x000b1;&#x000a0;9.1</td><td align="left">59.3&#x000a0;&#x000b1;&#x000a0;9.3</td></tr><tr><td align="left">&#x000a0;&#x02265;65&#x000a0;years, <italic>n</italic> (%)</td><td align="left">27 (34.6)</td><td align="left">28 (35.9)</td><td align="left">55 (35.3)</td></tr><tr><td align="left">Men, <italic>n</italic> (%)</td><td align="left">55 (70.5)</td><td align="left">56 (71.8)</td><td align="left">111 (71.2)</td></tr><tr><td align="left">Body weight (kg)</td><td align="left">68.9&#x000a0;&#x000b1;&#x000a0;11.6</td><td align="left">70.4&#x000a0;&#x000b1;&#x000a0;12.3</td><td align="left">69.7&#x000a0;&#x000b1;&#x000a0;11.9</td></tr><tr><td align="left">BMI (kg/m<sup>2</sup>)</td><td align="left">25.3&#x000a0;&#x000b1;&#x000a0;3.4</td><td align="left">26.0&#x000a0;&#x000b1;&#x000a0;3.1</td><td align="left">25.7&#x000a0;&#x000b1;&#x000a0;3.3</td></tr><tr><td align="left">HbA1c (%)</td><td align="left">8.1&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="left">8.1&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="left">8.1&#x000a0;&#x000b1;&#x000a0;0.8</td></tr><tr><td align="left">FPG (mmol/L)</td><td align="left">9.0&#x000a0;&#x000b1;&#x000a0;3.0</td><td align="left">8.7&#x000a0;&#x000b1;&#x000a0;2.0</td><td align="left">8.9&#x000a0;&#x000b1;&#x000a0;2.6</td></tr><tr><td align="left">&#x000a0;&#x02265;8.9&#x000a0;mmol/L, <italic>n</italic> (%)</td><td align="left">32 (41.0)</td><td align="left">32 (41.0)</td><td align="left">64 (41.0)</td></tr><tr><td align="left">Duration of T2DM (years)</td><td align="left">12.8&#x000a0;&#x000b1;&#x000a0;9.0</td><td align="left">12.9&#x000a0;&#x000b1;&#x000a0;8.1</td><td align="left">12.9&#x000a0;&#x000b1;&#x000a0;8.6</td></tr><tr><td align="left" colspan="3">eGFR (MDRD), mL/min/1.73&#x000a0;m<sup>2</sup>, <italic>n</italic> (%)</td><td align="left"/></tr><tr><td align="left">&#x000a0;Normal, &#x0003e;80</td><td align="left">65 (83.3)</td><td align="left">59 (75.6)</td><td align="left">124 (79.5)</td></tr><tr><td align="left">&#x000a0;Mild, &#x02265;50 to &#x02264;80</td><td align="left">12 (15.4)</td><td align="left">18 (23.1)</td><td align="left">30 (19.2)</td></tr><tr><td align="left">&#x000a0;Moderate, &#x02265;30 to &#x0003c;50</td><td align="left">1 (1.3)</td><td align="left">1 (1.3)</td><td align="left">2 (1.3)</td></tr><tr><td align="left">Background therapy</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">&#x000a0;Insulin dose (unit/kg/day)</td><td align="left">0.3&#x000a0;&#x000b1;&#x000a0;0.17</td><td align="left">0.3&#x000a0;&#x000b1;&#x000a0;0.20</td><td align="left">0.3&#x000a0;&#x000b1;&#x000a0;0.18</td></tr><tr><td align="left">&#x000a0;Insulin with concomitant metformin, <italic>n</italic> (%)</td><td align="left">34 (43.6)</td><td align="left">34 (43.6)</td><td align="left">68 (43.6)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Long- or Intermediate-acting, <italic>n</italic> (%)</td><td align="left">21 (26.9)</td><td align="left">20 (25.6)</td><td align="left">41 (26.3)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Pre-mixed, <italic>n</italic> (%)</td><td align="left">13 (16.7)</td><td align="left">14 (17.9)</td><td align="left">27 (17.3)</td></tr><tr><td align="left">&#x000a0;Insulin without concomitant metformin, <italic>n</italic> (%)</td><td align="left">44 (56.4)</td><td align="left">44 (56.4)</td><td align="left">88 (56.4)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Long- or Intermediate-acting, <italic>n</italic> (%)</td><td align="left">25 (32.1)</td><td align="left">25 (32.1)</td><td align="left">50 (32.1)</td></tr><tr><td align="left">&#x000a0;&#x000a0;Pre-mixed, <italic>n</italic> (%)</td><td align="left">19 (24.4)</td><td align="left">19 (24.4)</td><td align="left">38 (24.4)</td></tr><tr><td align="left">&#x000a0;Metformin (<italic>n</italic>)</td><td align="left">34</td><td align="left">34</td><td align="left">68</td></tr><tr><td align="left">&#x000a0;&#x000a0;Metformin total daily dose (mg/day)</td><td align="left">1022.1&#x000a0;&#x000b1;&#x000a0;497.6</td><td align="left">1073.5&#x000a0;&#x000b1;&#x000a0;446.1</td><td align="left">1047.8&#x000a0;&#x000b1;&#x000a0;469.7</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x02264;750&#x000a0;mg, <italic>n</italic> (%)</td><td align="left">17 (21.8)</td><td align="left">11 (14.1)</td><td align="left">28 (17.9)</td></tr><tr><td align="left">&#x000a0;&#x000a0;&#x000a0;&#x0003e;750&#x000a0;mg, <italic>n</italic> (%)</td><td align="left">17 (21.8)</td><td align="left">23 (29.5)</td><td align="left">40 (25.6)</td></tr></tbody></table><table-wrap-foot><p>Data are expressed as mean&#x000a0;&#x000b1;&#x000a0;SD, unless specified otherwise</p><p>
<italic>bid</italic> twice daily, <italic>BMI</italic> body mass index, <italic>eGFR</italic> estimated glomerular filtration rate, <italic>FPG</italic> fasting plasma glucose, <italic>HbA1c</italic> glycated hemoglobin, <italic>MDRD</italic> modification of diet in renal disease, <italic>SD</italic> standard deviation, <italic>T2DM</italic> type 2 diabetes mellitus</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Efficacy</title><p>The mean change in HbA1c over 12&#x000a0;weeks of treatment is represented in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a. Vildagliptin demonstrated consistent reductions in mean HbA1c compared to placebo throughout the study. The adjusted mean change in HbA1c from baseline to study endpoint was &#x02212;1.01&#x000a0;&#x000b1;&#x000a0;0.06 and &#x02212;0.11&#x000a0;&#x000b1;&#x000a0;0.06% in the vildagliptin and placebo groups, respectively, with a between-treatment difference of &#x02212;0.91&#x000a0;&#x000b1;&#x000a0;0.09% (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>b). The proportion of patients achieving target HbA1c &#x0003c;7% were distinctly higher in the vildagliptin group compared to placebo for all pre-defined responder categories (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Half the patients (38 out of 76) in the vildagliptin group achieved HbA1c target &#x0003c;7%, compared with 3.9% in the placebo group. In all the subgroups by concomitant metformin use or insulin type, vildagliptin resulted in higher HbA1c reductions than placebo (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Reductions in FPG were also consistent throughout the study (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a). The adjusted mean change in FPG from baseline to endpoint was &#x02212;1.2&#x000a0;&#x000b1;&#x000a0;0.2 vs. &#x02212;0.02&#x000a0;&#x000b1;&#x000a0;0.2&#x000a0;mmol/L in the vildagliptin and placebo groups, respectively, with a between-treatment difference of &#x02212;1.2&#x000a0;&#x000b1;&#x000a0;0.3&#x000a0;mmol/L (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001; Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>
<bold>a</bold> Mean HbA1c (%) by treatment and visit. Unadjusted means and standard errors (<italic>vertical</italic>
<italic>bars</italic>) are presented. Study endpoint is defined as the final available post-randomization assessment obtained at any visit (scheduled or unscheduled), prior to the start of major changes in insulin background therapy, up to the final scheduled visit including week 12. <italic>bid</italic> twice daily, <italic>BL</italic> baseline, <italic>EP</italic> endpoint, <italic>HbA1c</italic> glycated hemoglobin. <bold>b</bold> Change in HbA1c (%) from baseline to study endpoint. *<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001. Study endpoint is defined as the final available post-randomization assessment obtained at any visit (scheduled or unscheduled), prior to the start of major changes in insulin background therapy, up to the final scheduled visit including week 12. <italic>bid</italic> twice daily, <italic>BL</italic> baseline, <italic>HbA1c</italic> glycated hemoglobin, <italic>SE</italic> standard error</p></caption><graphic xlink:href="13300_2015_147_Fig3_HTML" id="MO3"/></fig><table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>HbA1c (%) responder rates (FAS)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Responder criteria</th><th align="left" colspan="2">Vildagliptin 50&#x000a0;mg bid (n&#x000a0;=&#x000a0;78)</th><th align="left">Placebo (n&#x000a0;=&#x000a0;78)</th></tr></thead><tbody><tr><td align="left">N&#x02032;<sup>a</sup>
</td><td align="left" colspan="2">78 (100)</td><td align="left">78 (100)</td></tr><tr><td align="left" colspan="4">Responder criterion</td></tr><tr><td align="left">&#x000a0;At least one criterion met</td><td align="left" colspan="2">67 (85.9)*</td><td align="left">21 (26.9)*</td></tr><tr><td align="left">&#x000a0;HbA1c &#x02264;6.5%<sup>b</sup>
</td><td align="left" colspan="2">23/77 (29.9)*</td><td align="left">2/78 (2.6)*</td></tr><tr><td align="left">&#x000a0;HbA1c &#x0003c;7.0%<sup>b</sup>
</td><td align="left" colspan="2">38/76 (50.0)*</td><td align="left">3/77 (3.9)*</td></tr><tr><td align="left">&#x000a0;HbA1c &#x0003c;7.0% in patients with baseline HbA1c &#x02264;8.0%<sup>c</sup>
</td><td align="left" colspan="2">33/42 (78.6)*</td><td align="left">3/37 (8.1)*</td></tr><tr><td align="left">&#x000a0;HbA1c reduction &#x02265;1.0%<sup>a</sup>
</td><td align="left" colspan="2">38 (48.7)*</td><td align="left">5 (6.4)*</td></tr><tr><td align="left">&#x000a0;HbA1c reduction &#x02265;0.5%<sup>a</sup>
</td><td align="left" colspan="2">62 (79.5)*</td><td align="left">20 (25.6)*</td></tr></tbody></table><table-wrap-foot><p>Chi-square test for vildagliptin 50&#x000a0;mg bid vs. placebo</p><p>
<italic>bid</italic> twice daily, <italic>HbA1c</italic> glycated hemoglobin, <italic>FAS</italic> full analysis set</p><p>*&#x000a0;<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001</p><p>
<sup>a</sup>Number (percentage) of patients with both baseline and endpoint HbA1c measurements, which were used as the denominator unless, specified otherwise</p><p>
<sup>b</sup>Denominator includes only patients with baseline HbA1c &#x02265;7% (&#x0003e;6.5%) and endpoint HbA1c measurement</p><p>
<sup>c</sup>Denominator includes only patients with 7% &#x02264;baseline HbA1c &#x02264;8% and endpoint HbA1c measurement</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Mean changes in HbA1c (%) from baseline to endpoint by subgroups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Treatment</th><th align="left">
<italic>n</italic>
</th><th align="left">Baseline mean (SE)</th><th align="left">Mean change (SE)</th><th align="left">Range</th></tr></thead><tbody><tr><td align="left" colspan="5">With metformin</td></tr><tr><td align="left">&#x000a0;Vildagliptin 50&#x000a0;mg bid</td><td char="." align="char">34</td><td align="left">8.2 (0.2)</td><td align="left">&#x02212;1.1 (0.1)</td><td align="left">(&#x02212;2.2 to &#x02212;0.1)</td></tr><tr><td align="left">&#x000a0;Placebo</td><td char="." align="char">34</td><td align="left">8.3 (0.2)</td><td align="left">&#x02212;0.1 (0.1)</td><td align="left">(&#x02212;1.1 to 1.2)</td></tr><tr><td align="left" colspan="5">Without metformin</td></tr><tr><td align="left">&#x000a0;Vildagliptin 50&#x000a0;mg bid</td><td char="." align="char">44</td><td align="left">8.0 (0.1)</td><td align="left">&#x02212;0.9 (0.1)</td><td align="left">(&#x02212;2.4 to 0.7)</td></tr><tr><td align="left">&#x000a0;Placebo</td><td char="." align="char">44</td><td align="left">8.0 (0.1)</td><td align="left">&#x02212;0.1 (0.1)</td><td align="left">(&#x02212;1.2 to 2.0)</td></tr><tr><td align="left" colspan="5">Insulin type: long-acting or intermediate-acting</td></tr><tr><td align="left">&#x000a0;Vildagliptin 50&#x000a0;mg bid</td><td char="." align="char">46</td><td align="left">8.0 (0.1)</td><td align="left">&#x02212;0.9 (0.1)</td><td align="left">(&#x02212;2.2 to 0.7)</td></tr><tr><td align="left">&#x000a0;Placebo</td><td char="." align="char">45</td><td align="left">8.3 (0.1)</td><td align="left">&#x02212;0.0 (0.1)</td><td align="left">(&#x02212;1.2 to 2.0)</td></tr><tr><td align="left" colspan="5">Insulin type: pre-mixed</td></tr><tr><td align="left">&#x000a0;Vildagliptin 50&#x000a0;mg bid</td><td char="." align="char">32</td><td align="left">8.2 (0.2)</td><td align="left">&#x02212;1.2 (0.1)</td><td align="left">(&#x02212;2.4 to &#x02212;0.3)</td></tr><tr><td align="left">&#x000a0;Placebo</td><td char="." align="char">33</td><td align="left">8.0 (0.2)</td><td align="left">&#x02212;0.2 (0.1)</td><td align="left">(&#x02212;1.1 to 1.0)</td></tr></tbody></table><table-wrap-foot><p>Baseline is the measurement obtained on day 1 or the sample obtained on an earlier visit (scheduled or unscheduled) which was closest to day 1, if day 1 measurement is missing. Study endpoint is defined as the final available post-randomization assessment obtained at any visit (scheduled or unscheduled), prior to the start of major changes in insulin background therapy, up to the final scheduled visit including week 12</p><p>
<italic>bid</italic> twice daily, <italic>HbA1c</italic> glycated hemoglobin, <italic>SE</italic> standard error</p></table-wrap-foot></table-wrap><fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>
<bold>a</bold> Mean FPG (mmol/L) by treatment and visit. Unadjusted means and standard errors (<italic>vertical</italic>
<italic>bars</italic>) are presented. <italic>bid</italic> twice daily, <italic>BL</italic> baseline, <italic>EP</italic> endpoint, <italic>FPG</italic> fasting plasma glucose. <bold>b</bold> Change in FPG (mmol/L) from baseline to endpoint by treatment. *<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001. Baseline is measurement obtained on day 1, or the sample obtained on an earlier visit (scheduled or unscheduled) which was closest to day 1, if day 1 measurement is missing. Study endpoint is defined as the final available post-randomization assessment obtained at any visit (scheduled or unscheduled), prior to the start of major changes in insulin background therapy, up to the final scheduled visit including week 12. <italic>bid</italic> twice daily, <italic>BL</italic> baseline, <italic>FPG</italic> fasting plasma glucose, <italic>SE</italic> standard error</p></caption><graphic xlink:href="13300_2015_147_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec10"><title>Safety</title><p>Vildagliptin 50&#x000a0;mg bid added to long-acting, intermediate-acting or pre-mixed insulin, with or without metformin was generally safe and well tolerated. The overall incidence of AEs was similar and comparable between the vildagliptin (46.2%) and placebo (43.6%) groups (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). The most frequent AEs were of the primary system organ class, &#x0201c;infections and infestations&#x0201d; with a slightly lower incidence in the vildagliptin group compared with placebo group (15.4% vs. 19.2%, respectively). The incidence of AEs was higher in the vildagliptin group for metabolism and nutrition disorders (6.4% vs. 1.3%) compared with placebo. The overall incidence of AEs suspected to be drug related was higher with vildagliptin (23.1%) compared with placebo (12.8%), and this difference was mainly due to events of hunger and hyperhidrosis. No deaths were reported during the study. The incidence of SAEs was infrequent in either of the treatment groups (2.6% in vildagliptin vs. 1.3% in placebo). Body weight remained almost unaltered throughout the study in the vildagliptin group (1.09&#x000a0;kg). The proportion of patients experiencing hypoglycemic events was higher in the vildagliptin group (6.4%, 5 patients) than placebo (1.3%, 1 patient). Nine hypoglycemic events were reported in the vildagliptin group as opposed to 1 event in the placebo group (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). Of the 9 events, 3 were triggered by strenuous exercise, 3 events by missed/delayed meals, and the remaining 3 events had no precipitating events specified. However, there was no severe hypoglycemia or any event reported, leading to study drug discontinuation. The overall incidence of hypoglycemic events was low and all hypoglycemic events were self-treatable using non-drug therapy.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Number (%) of patients who reported common AEs by preferred term (safety set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Preferred term, n (%)</th><th align="left">Vildagliptin 50&#x000a0;mg bid (<italic>n</italic>&#x000a0;=&#x000a0;78)</th><th align="left">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;78)</th></tr></thead><tbody><tr><td align="left">Any preferred term</td><td align="left">36 (46.2)</td><td align="left">34 (43.6)</td></tr><tr><td align="left">Nasopharyngitis</td><td align="left">10 (12.8)</td><td align="left">11 (14.1)</td></tr><tr><td align="left">Hyperhidrosis</td><td align="left">8 (10.3)</td><td align="left">2 (2.6)</td></tr><tr><td align="left">Hunger</td><td align="left">7 (9.0)</td><td align="left">3 (3.8)</td></tr><tr><td align="left">Tremor</td><td align="left">7 (9.0)</td><td align="left">4 (5.1)</td></tr><tr><td align="left">Asthenia</td><td align="left">6 (7.7)</td><td align="left">6 (7.7)</td></tr><tr><td align="left">Hypoglycemia</td><td align="left">5 (6.4)</td><td align="left">1 (1.3)</td></tr><tr><td align="left">Blood glucose decreased</td><td align="left">2 (2.6)</td><td align="left">2 (2.6)</td></tr><tr><td align="left">Constipation</td><td align="left">2 (2.6)</td><td align="left">1 (1.3)</td></tr><tr><td align="left">Dizziness</td><td align="left">2 (2.6)</td><td align="left">3 (3.8)</td></tr><tr><td align="left">Gastroenteritis</td><td align="left">2 (2.6)</td><td char="." align="char">0</td></tr><tr><td align="left">Palpitations</td><td align="left">2 (2.6)</td><td align="left">1 (1.3)</td></tr><tr><td align="left">Vision blurred</td><td align="left">2 (2.6)</td><td align="left">2 (2.6)</td></tr><tr><td align="left">Abdominal distension</td><td align="left">1 (1.3)</td><td align="left">2 (2.6)</td></tr><tr><td align="left">Cold sweat</td><td char="." align="char">0</td><td align="left">2 (2.6)</td></tr><tr><td align="left">Miliaria</td><td char="." align="char">0</td><td align="left">2 (2.6)</td></tr><tr><td align="left">Non-cardiac chest pain</td><td char="." align="char">0</td><td align="left">2 (2.6)</td></tr><tr><td align="left">Pharyngitis</td><td char="." align="char">0</td><td align="left">2 (2.6)</td></tr></tbody></table><table-wrap-foot><p>A patient with multiple occurrences of an AE under one treatment was counted only once in the AE category</p><p>
<italic>AE</italic> adverse event, <italic>bid</italic> twice daily</p></table-wrap-foot></table-wrap><table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Number of patients who experienced hypoglycemic events by event profile and treatment (safety set)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Vildagliptin 50&#x000a0;mg bid (<italic>n</italic>&#x000a0;=&#x000a0;78)</th><th align="left">Placebo (<italic>n</italic>&#x000a0;=&#x000a0;78)</th></tr></thead><tbody><tr><td align="left">Number (%) of patients with at least one hypoglycemic event</td><td align="left">5 (6.4)</td><td align="left">1 (1.3)</td></tr><tr><td align="left" colspan="3">Number of patients with</td></tr><tr><td align="left">&#x000a0;One hypoglycemic event</td><td align="left">3 (3.8)</td><td align="left">1 (1.3)</td></tr><tr><td align="left">&#x000a0;Two hypoglycemic events</td><td align="left">1 (1.3)</td><td char="." align="char">0</td></tr><tr><td align="left">&#x000a0;&#x0003e;2 hypoglycemic events</td><td align="left">1 (1.3)</td><td char="." align="char">0</td></tr><tr><td align="left">Total number of hypoglycemic events</td><td char="." align="char">9</td><td char="." align="char">1</td></tr><tr><td align="left" colspan="3">Severity grade</td></tr><tr><td align="left">&#x000a0;Grade 1<sup>a</sup>
</td><td align="left">9 (100)</td><td align="left">1 (100)</td></tr><tr><td align="left">&#x000a0;Grade 2<sup>b</sup>
</td><td char="." align="char">0</td><td char="." align="char">0</td></tr><tr><td align="left">&#x000a0;Suspected grade 2<sup>c</sup>
</td><td char="." align="char">0</td><td char="." align="char">0</td></tr></tbody></table><table-wrap-foot><p>Data are expressed as <italic>n</italic> (%), unless specified otherwise</p><p>
<italic>bid</italic> twice daily</p><p>Hypoglycemic events were defined as: <sup>a</sup> Grade 1: symptoms suggestive of hypoglycemia, where the patient was able to initiate self-treatment and plasma glucose measurement was&#x000a0;&#x0003c;56&#x000a0;mg/dL</p><p>
<sup>b</sup>Grade 2: symptoms suggestive of hypoglycemia, where the patient was unable to initiate self-treatment and plasma glucose measurement was&#x000a0;&#x0003c;56&#x000a0;mg/dL</p><p>
<sup>c</sup>Suspected grade 2: symptoms suggestive of hypoglycemia, where the patient was unable to initiate self-treatment and no plasma glucose measurement was available</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec11"><title>Discussion</title><p>This randomized, placebo-controlled, parallel-group study is the first report to demonstrate the efficacy and safety of vildagliptin 50&#x000a0;mg bid as add-on therapy in Japanese patients inadequately controlled on insulin, with or without concomitant metformin. In this study, vildagliptin treatment was well tolerated with a safety profile similar to placebo group and the results were consistent with earlier studies [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Vildagliptin 50&#x000a0;mg bid treatment demonstrated a clinically and statistically significant (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) reduction in HbA1c, with a between-treatment difference of &#x02212;0.91% after 12&#x000a0;weeks. Vildagliptin-mediated change in HbA1c was similar in patient subgroups treated with or without concomitant metformin. The efficacy results from this study are consistent with findings from previous trials conducted in Caucasian and Asian populations [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Vildagliptin treatment also resulted in significant reductions in FPG levels when compared with placebo, with a between-treatment difference of &#x02212;1.2&#x000a0;mmol/L (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001) which is comparable with previous findings from a 24-week clinical trial (a reduction of &#x02212;0.8&#x000a0;mmol/L in mean FPG from a baseline of 9.3&#x000a0;mmol/L) [<xref ref-type="bibr" rid="CR13">13</xref>]. Within subgroups based on insulin type as well as metformin use, vildagliptin demonstrated significantly marked reductions in HbA1c from baseline to endpoint, compared with placebo.</p><p>Similar and consistent differences in HbA1c values were observed in all responder rate categories. Half the patients in vildagliptin group achieved an HbA1c target &#x0003c;7%. Differences between treatment with vildagliptin and placebo were statistically significant for all responder rate categories.</p><p>Vildagliptin was well tolerated with overall incidence rate of AEs similar to that of placebo (46.2%, vildagliptin vs. 43.6%, placebo). The incidence of hyperhidrosis, hunger, tremor, and hypoglycemia was more common in the vildagliptin group than in the placebo group. The percentage of patients discontinued due to AEs was low and comparable between treatment groups. There were no patients with treatment-emergent hepatic enzyme elevation or deaths reported in the study. The overall incidence of hypoglycemic events was low in both the groups, but was higher in the vildagliptin-treated patients (6.4%, HbA1c ~7%) compared with placebo-treated patients (1.3%, HbA1c ~8%). None of the patients reported any severe hypoglycemia that required assistance of another person. Similar findings about a very low proportion of patients experiencing hypoglycemic events with vildagliptin treatment were reported in previous studies [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. Efficacy and safety findings observed from this study are in line with data obtained from other gliptins including alogliptin, saxagliptin, and linagliptin as add-on to insulin in terms of effective HbA1c reduction and similar incidence rates of AEs [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>Insulin therapy is generally associated with increased risk of hypoglycemia, which often is a barrier in achieving good glycemic control. Prolonged use of insulin is associated with IAH, which could also increase the risk of hypoglycemia and complications associated with it [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Furthermore, intensive glucose control resulted in severe hypoglycemia requiring assistance in 0.4&#x02013;1.5% as reported in ADVANCE (ClinicalTrials.gov Identifier, NCT00145925) and ACCORD trials (ClinicalTrials.gov Identifier, NCT00000620) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p><p>In the present study, addition of vildagliptin significantly reduced HbA1c by 1.0% in patients treated with a stable dose of insulin. In addition, there were no occurrences of any severe hypoglycemic events, suggesting that a combination therapy of insulin and vildagliptin might be effective in achieving glycemic control without additional risk of hypoglycemia.</p><p>The use of combination therapy with insulin and incretins, including DPP-4 inhibitors such as vildagliptin could be beneficial in patients with T2DM inadequately controlled on insulin due to their complementary mechanisms of action [<xref ref-type="bibr" rid="CR21">21</xref>].</p></sec><sec id="Sec12"><title>Conclusions</title><p>Treatment with vildagliptin 50&#x000a0;mg bid as add-on to insulin, with or without metformin therapy resulted in a statistically significant reduction in HbA1c in Japanese patients with T2DM. Despite significant improvement in glycemic control, few patients experienced hypoglycemic events with vildagliptin. Importantly, no patient experienced severe hypoglycemia requiring assistance of another person. The addition of vildagliptin could be an effective treatment option in Japanese patients inadequately controlled on insulin regardless of concomitant metformin therapy.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec13"><supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13300_2015_147_MOESM1_ESM.pdf"><caption><p>Supplementary material 1 (PDF 318&#x000a0;kb)</p></caption></media></supplementary-material></sec></sec></body><back><fn-group><fn><p>Dr. Hirose and Dr. Suzuki have contributed equally towards the manuscript and hold joint first authorship.
</p></fn></fn-group><ack><p>The authors would like to thank the patients and staff who participated in this study. Sponsorship and article processing charges for this study were funded by Novartis Pharma K.K. The authors take full responsibility for the content of the manuscript, and they participated in all stages of manuscript development and approved the final manuscript for publication. Takahisa Hirose and Manabu Suzuki contributed to the study design, data analysis, interpretation, and drafting of the manuscript. Isao Tsumiyama contributed towards study design, data interpretation, and statistical analysis. All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship, had full access to the study data and take complete responsibility for the integrity of the data and accuracy of the data analysis. Medical writing assistance, editorial assistance, and the collation and incorporation of comments from all authors for this study were provided by Rangan Gupta (Novartis Healthcare Pvt. Ltd., Hyderabad, India).</p><sec id="FPar1"><title>Disclosures</title><p>Manabu Suzuki and Isao Thumiyama are employees of Novartis Pharma KK. Takahisa Hirose is independent medical advisor for this study and has received consultancy fees, lecture fee or research funding from Novartis Pharma KK, Sanofi Eli Lilly Co., Novo Nordisk Pharma Ltd., Takeda Pharmaceutical Co. Ltd., Daiichisankyo Co. Ltd., MitsubishiTanabe Pharma Corp., DainipponSumitomo, AstraZeneca, TaishoToyama Pharmaceutical Co. Ltd., Asteras Pharma, Inc., Ono Pharmaceutical. Co. Ltd., MSD, Kissei Pharmaceutical Co., Ltd., Boehringer Ingelheim.</p></sec><sec id="FPar2"><title>List of investigators/institutions</title><p>Tomio Inoue (Ageo Central General Hospital), Noritaka Onoda (Sayama Sogo Clinic), Kazunori Ogino (Ogino Clinic), Tatsuhiro Shimoyama (Shimamura Kinen Hospital), Takashi Iizuka (Asahi Internal Medicine Clinic), Koki Shin (Shin Clinic), Zenji Makita (AGE Makita Medical Clinic), Isao Uchimura (Chiyodahoujin Clinic), Masayuki Hosoi (Osaka City General Hospital), Shizuka Kaneko (Takatsuki Red Cross Hospital), Ryoko Takei (Fukuoka Teishin Hospital), Yasuyuki Kihara (Kitakyushu General Hospital), Yoshihide Fukumoto (Fukumoto Clinic), Souichi Uekihara (Japanese Red Cross Kumamoto Hospital), Shizuo Kajiyama (Kajiyama Clinic), Kojiro Ichikawa (Fukutsu Medical Clinic), Seika Kato (Hirakata Kohsai Hospital), Tatsushi Sugiura (Seiwa Clinic), Hiroaki Seino (Seino Internal Medicine Clinic), Masae Minami (Clinic Masae Minami), Yukari Shimizu (Shimizu Clinic Fusa), Ryohei Yoshimura (Yoshimura Clinic), Fuminobu Okuguchi (Okuguchi Clinic of internal medicine), Hideo Takahashi (Minami Akatsuka Clinic), Yoshimitsu Yamasaki (Medical Corporation Kyosokai AMC Nishi-umeda Clinic), Yumiko Ide (Tokyo Center Clinic), Arihiro Kiyosue (Tokyo-Eki Center-building Clinic), Kengo Kaneko (Kumamoto Rosai Hospital).</p></sec><sec id="FPar3"><title>Compliance with ethics guidelines</title><p>The study protocol was reviewed and approved by the Independent Ethics Committee/Institutional Review Board at each participating center. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national), the Declaration of Helsinki of 1964, as revised in 2013 and Good Clinical Practice guidelines. Written informed consent was obtained from all patients prior to inclusion in the study.</p></sec><sec id="d30e1799"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, Belgium: International Diabetes Federation, 2013. <ext-link ext-link-type="uri" xlink:href="http://www.idf.org/diabetesatlas/6e/diabetes">http://www.idf.org/diabetesatlas/6e/diabetes</ext-link>. Accessed 9 Jul 2015.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawamori</surname><given-names>R</given-names></name></person-group><article-title>Diabetes trends in Japan</article-title><source>Diabetes Metab Res Rev.</source><year>2002</year><volume>18</volume><fpage>S9</fpage><lpage>S13</lpage><pub-id pub-id-type="doi">10.1002/dmrr.296</pub-id><pub-id pub-id-type="pmid">12324979</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neville</surname><given-names>SE</given-names></name><name><surname>Boye</surname><given-names>KS</given-names></name><name><surname>Montgomery</surname><given-names>WS</given-names></name><name><surname>Iwamoto</surname><given-names>K</given-names></name><name><surname>Okamura</surname><given-names>M</given-names></name><name><surname>Hayes</surname><given-names>RP</given-names></name></person-group><article-title>Diabetes in Japan: a review of disease burden and approaches to treatment</article-title><source>Diabetes Metab Res Rev.</source><year>2009</year><volume>25</volume><fpage>705</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1002/dmrr.1012</pub-id><pub-id pub-id-type="pmid">19795421</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namba</surname><given-names>M</given-names></name><name><surname>Katsuno</surname><given-names>T</given-names></name><name><surname>Kusunoki</surname><given-names>Y</given-names></name><name><surname>Matsuo</surname><given-names>T</given-names></name><name><surname>Miuchi</surname><given-names>M</given-names></name><name><surname>Miyagawa</surname><given-names>J</given-names></name></person-group><article-title>New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy</article-title><source>Clin Exp Nephrol.</source><year>2012</year><volume>17</volume><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s10157-012-0709-0</pub-id><pub-id pub-id-type="pmid">23135865</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Japan Diabetes Society. Treatment Guide for Diabetes. 2012&#x02013;2013 Edited by Japan Diabetes Society. Bunkodo Co. Ltd. <ext-link ext-link-type="uri" xlink:href="http://www.jds.or.jp/modules/en/index.php?content_id=27">http://www.jds.or.jp/modules/en/index.php?content_id=27</ext-link>. Accessed 29 Jul 2015.</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzucchi</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Diamant</surname><given-names>M</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><etal/></person-group><article-title>Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)</article-title><source>Diabetologia</source><year>2012</year><volume>55</volume><fpage>1577</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1007/s00125-012-2534-0</pub-id><pub-id pub-id-type="pmid">22526604</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadowaki</surname><given-names>T</given-names></name><name><surname>Tajima</surname><given-names>N</given-names></name><name><surname>Odawara</surname><given-names>M</given-names></name><name><surname>Minamide</surname><given-names>T</given-names></name><name><surname>Kawashima</surname><given-names>M</given-names></name><name><surname>Yanagida</surname><given-names>D</given-names></name><etal/></person-group><article-title>Efficacy and safety of sitagliptin add-on therapy in Japanese patients with type 2 diabetes on insulin monotherapy</article-title><source>Diabetol Int</source><year>2013</year><volume>4</volume><fpage>160</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1007/s13340-013-0109-z</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Home</surname><given-names>P</given-names></name><name><surname>Naggar</surname><given-names>NE</given-names></name><name><surname>Khamseh</surname><given-names>M</given-names></name><name><surname>Gonzalez-Galvez</surname><given-names>G</given-names></name><name><surname>Shen</surname><given-names>C</given-names></name><name><surname>Chakkarwar</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name></person-group><article-title>An observational non interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries the A1chieve study</article-title><source>Diabetes Res Clin Pract</source><year>2011</year><volume>94</volume><fpage>352</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2011.10.021</pub-id><pub-id pub-id-type="pmid">22153567</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohamed</surname><given-names>M</given-names></name></person-group><article-title>An audit on diabetes management in Asian patients treated by specialists: the Diabcare-Asia 1998 and 2003 studies</article-title><source>Curr Med Res Opin</source><year>2008</year><volume>24</volume><fpage>507</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1185/030079908X261131</pub-id><pub-id pub-id-type="pmid">18184454</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noh</surname><given-names>RM</given-names></name><name><surname>Graveling</surname><given-names>AJ</given-names></name><name><surname>Frier</surname><given-names>BM</given-names></name></person-group><article-title>Medically minimizing the impact of hypoglycemia in type 2 diabetes: a review</article-title><source>Expert Opin Pharmacother</source><year>2011</year><volume>12</volume><fpage>2161</fpage><lpage>2175</lpage><pub-id pub-id-type="doi">10.1517/14656566.2011.589835</pub-id><pub-id pub-id-type="pmid">21668402</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graveling</surname><given-names>AJ</given-names></name><name><surname>Frier</surname><given-names>BM</given-names></name></person-group><article-title>Impaired awareness of hypoglycemia: a review</article-title><source>Diabetes Metab.</source><year>2010</year><volume>36</volume><fpage>S64</fpage><lpage>S74</lpage><pub-id pub-id-type="doi">10.1016/S1262-3636(10)70470-5</pub-id><pub-id pub-id-type="pmid">21211739</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oishi</surname><given-names>M</given-names></name><name><surname>Yamazaki</surname><given-names>K</given-names></name><name><surname>Okaguchi</surname><given-names>F</given-names></name><name><surname>Sugimoto</surname><given-names>H</given-names></name><name><surname>Kanatsuka</surname><given-names>A</given-names></name><collab>Japan Diabetes Clinical Data Management Study Group</collab></person-group><article-title>Kashiwagi A Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002&#x02013;2011 in Japan (JDDM32)</article-title><source>J Diabetes Investig.</source><year>2014</year><volume>5</volume><fpage>581</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1111/jdi.12183</pub-id><pub-id pub-id-type="pmid">25411627</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kothny</surname><given-names>W</given-names></name><name><surname>Foley</surname><given-names>JE</given-names></name><name><surname>Kozlovski</surname><given-names>P</given-names></name><name><surname>Shao</surname><given-names>Q</given-names></name><name><surname>Gallwitz</surname><given-names>B</given-names></name><name><surname>Lukashevich</surname><given-names>V</given-names></name></person-group><article-title>Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus</article-title><source>Diabetes Obes Metab</source><year>2013</year><volume>15</volume><fpage>252</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1111/dom.12020</pub-id><pub-id pub-id-type="pmid">23039321</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozlovski</surname><given-names>P</given-names></name><name><surname>Foley</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>Q</given-names></name><name><surname>Lukashevich</surname><given-names>V</given-names></name><name><surname>Kothny</surname><given-names>W</given-names></name></person-group><article-title>Vildagliptin-insulin combination improves glycemic control in Asians with type 2 diabetes</article-title><source>World J Diabetes.</source><year>2013</year><volume>4</volume><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.4239/wjd.v4.i4.151</pub-id><pub-id pub-id-type="pmid">23961326</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Ning G, Wang W, Li L, Ma J, Lv X; all investigators, Yang M, Wang W, Woloschak M, Lukashevich V, Kothny W. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. J Diabetes. 2015. doi:10.1111/1753-0407.12303. (<bold>Epub ahead of print</bold>).</mixed-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Rendell</surname><given-names>MS</given-names></name><name><surname>Gross</surname><given-names>JL</given-names></name><name><surname>Fleck</surname><given-names>PR</given-names></name><name><surname>Wilson</surname><given-names>CA</given-names></name><name><surname>Mekki</surname><given-names>Q</given-names></name></person-group><article-title>Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia</article-title><source>Diabetes Obes Metab</source><year>2009</year><volume>11</volume><fpage>1145</fpage><lpage>1152</lpage><pub-id pub-id-type="doi">10.1111/j.1463-1326.2009.01124.x</pub-id><pub-id pub-id-type="pmid">19758359</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnett</surname><given-names>AH</given-names></name><name><surname>Charbonnel</surname><given-names>B</given-names></name><name><surname>Donovan</surname><given-names>M</given-names></name><name><surname>Fleming</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name></person-group><article-title>Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin</article-title><source>Curr Med Res Opin</source><year>2012</year><volume>28</volume><fpage>513</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1185/03007995.2012.665046</pub-id><pub-id pub-id-type="pmid">22313154</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yki-J&#x000e4;rvinen</surname><given-names>H</given-names></name><name><surname>Rosenstock</surname><given-names>J</given-names></name><name><surname>Dur&#x000e1;n-Garcia</surname><given-names>S</given-names></name><name><surname>Pinnetti</surname><given-names>S</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Thiemann</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Woerle</surname><given-names>HJ</given-names></name></person-group><article-title>Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a&#x000a0;&#x02265;&#x000a0;52-week randomized, double-blind study</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>3875</fpage><lpage>3881</lpage><pub-id pub-id-type="doi">10.2337/dc12-2718</pub-id><pub-id pub-id-type="pmid">24062327</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ADVANCE Collaborative Group</collab><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Neal</surname><given-names>B</given-names></name><name><surname>Billot</surname><given-names>L</given-names></name><etal/></person-group><article-title>Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2560</fpage><lpage>2572</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0802987</pub-id><pub-id pub-id-type="pmid">18539916</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Action to Control Cardiovascular Risk in Diabetes Study Group</collab><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Miller</surname><given-names>ME</given-names></name><name><surname>Byington</surname><given-names>RP</given-names></name><name><surname>Goff</surname><given-names>DC</given-names><suffix>Jr</suffix></name><name><surname>Bigger</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Effects of intensive glucose lowering in type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2545</fpage><lpage>2559</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0802743</pub-id><pub-id pub-id-type="pmid">18539917</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahr&#x000e9;n</surname><given-names>B</given-names></name></person-group><article-title>Insulin plus incretin: a glucose-lowering strategy for type 2-diabetes</article-title><source>World J Diabetes.</source><year>2014</year><volume>5</volume><fpage>40</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.4239/wjd.v5.i1.40</pub-id><pub-id pub-id-type="pmid">24567800</pub-id></element-citation></ref></ref-list></back></article>